首页> 外文期刊>Oncology letters >Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications
【24h】

Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications

机译:DLC1肿瘤抑制蛋白协调异位表达的合作抗增殖效应,肝癌细胞中MYC癌症表达的沉默:治疗含义

获取原文
获取原文并翻译 | 示例
           

摘要

Human hepatocellular carcinoma (HCC) is one of the most common types of cancer and has a very poor prognosis; thus, the development of effective therapies for the treatment of advanced HCC is of high clinical priority. In the present study, the anti-oncogenic effect of combined knockdown of c-Myc expression and ectopic restoration of deleted in liver cancer 1 (DLC1) expression was investigated in human liver cancer cells. Expression of c-Myc in human HCC cells was knocked down by stable transfection with a Myc-specific short hairpin (sh) RNA vector. DLC1 expression in Huh7 cells was restored by adenovirus transduction, and the effects of DLC1 expression and c-Myc knockdown on Ras homolog gene family, member A (RhoA) levels, cell proliferation, soft agar colony formation and cell invasion were measured. Downregulation of c-Myc or re-expression of DLC1 led to a marked reduction in RhoA levels, which was associated with decreases in cell proliferation, soft agar colony formation and invasiveness; this inhibitory effect was augmented with a combination of DLC1 transduction and c-Myc suppression. To determine whether liver cell-specific delivery of DLC1 was able to enhance the inhibitory effect of c-Myc knockdown on tumor growth in vivo, DLC1 vector DNA complexed with galactosylated polyethylene glycol-linear polyethyleneimine was administered by tail vein injection to mice bearing subcutaneous xenografts of Huh7 cells transfected with shMyc or control shRNA. A cooperative inhibitory effect of DLC1 expression and c-Myc knockdown on the growth of Huh7-derived tumors was observed, suggesting that targeted liver cell delivery of DLC1 and c-Myc shRNA may serve as a possible gene therapy modality for the treatment of human HCC.
机译:人类肝细胞癌(HCC)是最常见的癌症类型之一,预后非常差;因此,用于治疗晚期HCC的有效疗法的发展具有很高的临床优先权。在本研究中,在人肝癌细胞中研究了肝癌1(DLC1)表达中缺失的C-Myc表达和异位恢复的抗致癌效果。通过用Myc特异性短发夹(SH)RNA载体的稳定转染,通过稳定转染,通过稳定转染,通过稳定的转染敲击人HCC细胞中的表达。通过腺病毒转导恢复HUH7细胞中的DLC1表达,并测量DLC1表达和C-MYC敲低对RAS同源物基因的影响,测定了成员A(RHOA)水平,细胞增殖,软琼脂菌落形成和细胞侵袭。 C-MYC的下调或DLC1的重新表达导致RHOA水平的显着降低,这与细胞增殖的降低有关,软琼脂菌落形成和侵袭性有关;通过DLC1转导和C-MYC抑制的组合增强该抑制作用。为了确定DLC1的肝细胞特异性递送是否能够增强C-MYC敲低对体内肿瘤生长的抑制作用,通过尾静脉注射用尾静脉注射络合与半乳糖基化的聚乙二醇 - 线性聚乙烯络合的DLC1载体DNA与皮下异种移植物的小鼠施用用SHMYC或控制shRNA转染HUH7细胞。观察到DLC1表达和C-MYC敲低对HUH7衍生肿瘤生长的合作抑制作用,表明DLC1和C-MYC ShRNA的靶向肝细胞递送可作为治疗人HCC治疗的可能基因治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号